BPBT
SAGE

Boston Private Bank & Trust’s Sage Therapeutics SAGE Stock Holding History

Boston Private Bank & Trust’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,000
Closed -$37K – 1104
2014
Q4 		$37K Buy
+1,000
New +$37.3K ﹤0.01% 632

Other funds holding SAGE

TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Boston Private Bank & Trust's SAGE Position: Q1 2015 in Review

Boston Private Bank & Trust sold out of Sage Therapeutics (SAGE) in Q1 2015, closing a stake of 1,000 shares — an estimated $37K sold.

Boston Private Bank & Trust first reported a position in SAGE in Q4 2014 and held it in 1 quarter. The position peaked at $37K in Q4 2014. 92 funds tracked by Wall St. Rank hold SAGE as of Q1 2015.

  • Boston Private Bank & Trust reported no remaining Sage Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Boston Private Bank & Trust sold 1,000 Sage Therapeutics shares in Q1 2015, an estimated $37K.
  • Boston Private Bank & Trust first reported a position in Sage Therapeutics in Q4 2014 and held it in 1 quarter.
  • Boston Private Bank & Trust's Sage Therapeutics position peaked at $37K in Q4 2014.
  • 92 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2015.

Based on Boston Private Bank & Trust's 13F filing for Q1 2015, filed 9 Apr 2015.